State of the art and future directions of pancreatic ductal adenocarcinoma therapy

Neuzillet, Cindy; Tijeras‐Raballand, Annemilaï; Bourget, Philippe; Cros, Jérôme; Couvelard, Anne; Sauvanet, Alain; Vullierme, Marie‐Pierre; Tournigand, Christophe; Hammel, Pascal

doi:10.1016/j.pharmthera.2015.08.006

Cited by 88 publications

(68 citation statements)

References 282 publications

(254 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, in this study of Luberice and co-workers it was observed that the number of patients resected for PDAC who survived more than 5 years did not changed over the years (9). Nevertheless, the prognosis of a patient resected for PDAC is mainly determined by tumor-related factors such as tumor diameter, lymph nodes involvement, differentiation grade, resection margins status and completion of adjuvant therapy (10).…”

Section: Resectable Pdacmentioning

confidence: 86%

“…The imaging method of choice for the assessment of resectability in a patient with PDAC is the thoraco-abdomino-pelvic multiple detector-computed tomography with thin sections, non-enhanced, late arterial and portal venous phases and reconstructions (so called "pancreas protocol") (10). The computed tomography of a localized, resectable PDAC should demonstrate no distant metastases, no evidence of superior mesenteric vein/ portal vein abutment, distortion, tumor thrombus or venous encasement and clear fat planes around the celiac trunk, hepatic artery and superior mesenteric artery (11).…”

Section: Resectable Pdacmentioning

confidence: 99%

“…The current standard strategy for a patient with resectable PDAC is resection (i.e., pancreatectomy) followed by adjuvant chemotherapy (10). For resectable PDAC, pancreatectomy was associated with a statistically significant increase in survival, compared with any other therapy (12).…”

Section: Resectable Pdacmentioning

confidence: 99%

“…Unfortunately, resection is feasible in a limited number of patients with PDAC (15 -20%) (10,13). A recent study has shown that even with resection the number of patients with PDAC who survived more than 5 years is very low (10.1%) (14).…”

Section: Resectable Pdacmentioning

confidence: 99%

“…A locally advanced PDAC is usually considered as a primary unresectable disease and is defined by the absence of distant metastases with portal vein/ superior mesenteric vein involvement that do not allows reconstruction and/ or invasion of the aorta/ inferior vena cava and/ or superior mesenteric artery encasement more than 180 degrees (for PDAC of the pancreatic head) and/ or celiac trunk abutment (for PDAC of the pancreatic head) and/ or superior mesenteric artery encasement (for PDAC of the distal pancreas) and/ or enchasement of the celiac trunk over 180 degrees (for PDAC of the distal pancreas) (10).…”

Section: Locally Advanced Pdac -Conversion Therapymentioning

confidence: 99%

See 4 more Smart Citations

Onco-surgical Strategies in Pancreatic Ductal Adenocarcinoma

Popescu¹,

Dumitraşcu²

2017

SGO

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is an important healthcare problem because is a leading cause of death by cancer. PDAC is a highly lethal disease with a very dismal prognosis. Most patients present advanced disease at diagnosis. The management of a patient diagnosed with PDAC should be discussed in a multidisciplinary team in high-volume centers. Pancreatectomy represents the single hope of long-term survival for a patient with PDAC but the resectability rate is less than 20% of the cases. Several progresses were observed in the last years regarding the surgical and oncological approach for PDAC. The aim of the paper is to make a brief review of the current onco-surgical strategies available for patients with PDAC.

show abstract

Section: Resectable Pdacmentioning

confidence: 86%

Section: Resectable Pdacmentioning

confidence: 99%

Section: Resectable Pdacmentioning

confidence: 99%

Section: Resectable Pdacmentioning

confidence: 99%

Section: Locally Advanced Pdac -Conversion Therapymentioning

confidence: 99%

See 3 more Smart Citations

Onco-surgical Strategies in Pancreatic Ductal Adenocarcinoma

Popescu¹,

Dumitraşcu²

2017

SGO

View full text Add to dashboard Cite

show abstract

LncRNA LOXL1‐AS1/miR‐28‐5p/SEMA7A axis facilitates pancreatic cancer progression

Liu

Guo

et al. 2019

Cell Biochemistry & Function

View full text Add to dashboard Cite

Pancreatic cancer (PC), one of the most aggressive and lethal human malignancies, is associated with a deplorable prognosis despite progressive therapeutic strategies.Emerging evidence manifests that miR-28-5p is involved in several cancers, and its descending expression is associated with poor prognosis. Nevertheless, the function of miR-28-5p in PC remains unclear. Thus, the underlying regulatory mechanism of miR-28-5p in PC is urgent to be clarified. In the present study, we first recognized miR-28-5p was downregulated in PC, and miR-28-5p overexpression inhibited cell proliferation and migration in PC. Then miR-28-5p was verified to act as a molecular sponge of LOXL1-AS1. Therefore, the function of LOXL1-AS1 was further explored in PC, presenting that LOXL1-AS1 suppression inhibited cell proliferation and migration. What is more, SEMA7A was found to be a target gene for miR-28-5p and was upregulated in PC. In addition, LOXL1-AS1 could positively regulate SEMA7A expression while miR-28-5p could negatively regulate SEMA7A expression. According to rescue experiments, SEMA7A overexpression partially neutralized LOXL1-AS1 silence-mediated inhibitory function on progression in PC. Taken together, all the data demonstrated that LOXL1-AS1/miR-28-5p/SEMA7A axis facilitated pancreatic cancer progression, which may be regarded as an innovative therapeutic target for PC treatment.Significance of the study: Our findings constitute the first report to delineate that lncRNA LOXL1-AS1/miR-28-5p/SEMA7A axis facilitates PC progression. According to our experimental results, we found the expression of miR-28-5p was downregulated in PC cells and miR-28-5p overexpression inhibited cell proliferation and migration in PC. LOXL1-AS1 could sponge miR-28-5p and then upregulate the expression of SEMA7A. Thus, LOXL1-AS1/miR-28-5p/SEMA7A axis facilitated PC progression. This initially proposed point might provide a novel molecular target for PC treatment.

show abstract

Long non‐coding RNA lnc‐PCTST predicts prognosis through inhibiting progression of pancreatic cancer by downregulation of TACC‐3

Wang

Ding

et al. 2018

Intl Journal of Cancer

View full text Add to dashboard Cite

Pancreatic cancer (PC), which is one of the most lethal of malignancies and a major health burden, is associated with a dismal prognosis despite current therapeutic advances. Numerous long noncoding RNAs (lncRNA) have shown to be essential for PC tumorigenesis and progression. Nevertheless, the exact expression pattern of lnc-PCTST and its clinical significance still remain unclear. This study investigates the expression pattern of lnc-PCTST and its associated mRNA in three paired PC tissues and adjacent non-tumor tissues by Microarray-coarray approach. Briefly, our data demonstrated that lnc-PCTST expression is down-regulated in PC tissues. Also, lnc-PCTST has shown to be negatively correlated with transforming acidic coiled-coil 3 (TACC-3) expression. This expression pattern was further confirmed following qRT-PCR validation of 34 out of 48 paired cancer tissues. Furthermore, lnc-PCTST overexpression in PC cell lines inhibited cell proliferation and invasion in vitro, and tumorigenesis in vivo (using nude mice as animal model), but did not altered cell migration. Moreover, lnc-PCTST overexpression increased E-cadherin and repressed vimentin expression in vitro. Additionally, TACC-3 knockdown simulated the inhibiting effect of lnc-PCTST overexpression on PC cell lines, and the impaired proliferation, invasion effect and E-cadherin, vimentin expression on lnc-PCTST over-expressed cell lines can be rescued by overexpressed TACC-3. Significantly, the expression of lnc-PCTST was closely associated with its genomic neighboring gene TACC-3 and inhibited its promoter activity. In conclusion, lnc-PCTST is a potential tumor suppressor in PC, which inhibits cell proliferation, invasion, tumorigenesis and EMT by modulating TACC-3.

show abstract

State of the art and future directions of pancreatic ductal adenocarcinoma therapy

Cited by 88 publications

References 282 publications

Onco-surgical Strategies in Pancreatic Ductal Adenocarcinoma

Onco-surgical Strategies in Pancreatic Ductal Adenocarcinoma

LncRNA LOXL1‐AS1/miR‐28‐5p/SEMA7A axis facilitates pancreatic cancer progression

Long non‐coding RNA lnc‐PCTST predicts prognosis through inhibiting progression of pancreatic cancer by downregulation of TACC‐3

Contact Info

Product

Resources

About